Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EDNRB | P24530 | 5/20 | 0.52 |
| ▸ | EDNRA | P25101 | 3/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858304 | 0.90 | PLA2G2A (0.51) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6855171 | 0.85 | KMT2A (0.49) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6858282 | 0.84 | PLA2G2A (0.49) | PLA2G2AKMT2AEDNRBEDNRA | |
| SCHEMBL6851257 | 0.82 | PLA2G2A (0.53) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6851227 | 0.82 | PLA2G2A (0.47) | PLA2G2AKMT2AEDNRBEDNRA | |
| SCHEMBL6856189 | 0.82 | KMT2A (0.49) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6851204 | 0.82 | PLA2G2A (0.53) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6855746 | 0.81 | KMT2A (0.46) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6858367 | 0.81 | KMT2A (0.47) | PLA2G2AKMT2AEDNRBEDNRAMAPK8 | |
| SCHEMBL6855557 | 0.80 | KMT2A (0.49) | PLA2G2AKMT2AEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| EP-1341761-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002030895-A1 | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-η BINDING AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | PLA2G2A 533/4885KMT2A 2753/4885EDNRB 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.